According to GuruFocus Insider Data, the largest CFO buys during the past week were Fuller(Hb) Co, Spectrum Pharma, NAIC Growth Fund Inc, and Biosante Pharma.
Fuller(Hb) Co (FUL, Financial): Senior VP and CFO James R Giertz Bought 5,000 Shares
Senior VP and CFO of Fuller(Hb) Co (FUL) James R Giertz bought 5,000 shares on 01/14/2011 at an average price of $22.48. H.B. Fuller Company is a worldwide manufacturer and marketer of adhesives, sealants, coatings, paints and other specialty chemical products. Fuller(hb) Co has a market cap of $1.12 billion; its shares were traded at around $22.91 with a P/E ratio of 14.4 and P/S ratio of 0.8. The dividend yield of Fuller(hb) Co stocks is 1.2%. Fuller(hb) Co had an annual average earning growth of 6.5% over the past 10 years.
H.B. Fuller Company reported financial results for the fourth quarter and fiscal year that ended November 27, 2010. Net revenue for the fourth quarter of 2010 was $360.2 million, up 5.5 percent versus the fourth quarter of 2009. Net income for the fourth quarter of 2010 was $21.9 million, or $0.44 per diluted share, versus $24.6 million, or $0.50 per diluted share, in last year’s fourth quarter.
>Hedge Fund Gurus that owns FUL: Kenneth Fisher of Fisher Asset Management, LLC, Jim Simons of Renaissance Technologies LLC, Steven Cohen of SAC Capital Advisors. Mutual Fund and Other Gurus that owns FUL: Bill Frels of Mairs & Power Inc. , Mario Gabelli of GAMCO Investors, Chuck Royce of Royce& Associates.
Senior VP and CFO James R Giertz bought shares of FUL stock.
For details of insider trades and ownership of FUL, click here
Spectrum Pharma (SPPI, Financial): Acting CFO Brett L Scott Bought 4,000 Shares
Acting CFO of Spectrum Pharma (SPPI) Brett L Scott bought 4,000 shares on 01/20/2011 at an average price of $6.05. Spectrum Pharmaceuticals, Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum Pharma has a market cap of $316.5 million; its shares were traded at around $6.33 with and P/S ratio of 8.3.
Spectrum Pharmaceuticals, Inc. reported financial results for the three and nine-months ended September 30. The Company recorded a net loss of $4.6 million, or ($0.09) per basic and diluted share, compared to net income of $474 thousand, or $0.01 per basic and ($0.07) per diluted share, in the third quarter of 2009.
Acting CFO Brett L Scott and CSO AND HEAD OF R&D OPERATIONS George F Tidmarsh bought shares of SPPI stock.
For details of insider trades and ownership of SPPI, click here
NAIC Growth Fund Inc (GRF, Financial): CFO, COO and secretary David C Sims Bought 1,667 Shares
CFO, COO and secretary of NAIC Growth Fund Inc (GRF) David C Sims bought 1,667 shares on 01/19/2011 at an average price of $6.55. Naic Growth Fund Inc has a market cap of $26.6 million; its shares were traded at around $6.6501 . The dividend yield of Naic Growth Fund Inc stocks is 1.5%.
President and CEO Luke E Sims sold shares of GRF stock.
Biosante Pharma (BPAX, Financial): Sr. VP of Finance, CFO & Sec'y Philip B Donenberg Bought 2,000 Shares
Sr. VP of Finance, CFO & Sec'y of Biosante Pharma (BPAX) Philip B Donenberg bought 2,000 shares during the past week at an average price of $1.88. Biosante Pharmaceutical is an emerging pharmaceutical company developing a pipeline of hormone therapy products to treat both men and women. Biosante Pharma has a market cap of $132.4 million; its shares were traded at around $1.87 with and P/S ratio of 105.2.
BioSante Pharmaceuticals, Inc. announced its third quarter 2010 financial results. BioSante incurred a net loss of approximately $11.6 million or ($0.16) per share for the quarter ended September 30, 2010, compared to a net loss of $6.4 million or ($0.21) per share for the same period in 2009.
Vice Chairman, President & CEO Stephen M Simes, Director Louis W Sullivan, and Director Ross J Mangano bought shares of BPAX stock.
For details of insider trades and ownership of BPAX, click here
Fuller(Hb) Co (FUL, Financial): Senior VP and CFO James R Giertz Bought 5,000 Shares
Senior VP and CFO of Fuller(Hb) Co (FUL) James R Giertz bought 5,000 shares on 01/14/2011 at an average price of $22.48. H.B. Fuller Company is a worldwide manufacturer and marketer of adhesives, sealants, coatings, paints and other specialty chemical products. Fuller(hb) Co has a market cap of $1.12 billion; its shares were traded at around $22.91 with a P/E ratio of 14.4 and P/S ratio of 0.8. The dividend yield of Fuller(hb) Co stocks is 1.2%. Fuller(hb) Co had an annual average earning growth of 6.5% over the past 10 years.
H.B. Fuller Company reported financial results for the fourth quarter and fiscal year that ended November 27, 2010. Net revenue for the fourth quarter of 2010 was $360.2 million, up 5.5 percent versus the fourth quarter of 2009. Net income for the fourth quarter of 2010 was $21.9 million, or $0.44 per diluted share, versus $24.6 million, or $0.50 per diluted share, in last year’s fourth quarter.
>Hedge Fund Gurus that owns FUL: Kenneth Fisher of Fisher Asset Management, LLC, Jim Simons of Renaissance Technologies LLC, Steven Cohen of SAC Capital Advisors. Mutual Fund and Other Gurus that owns FUL: Bill Frels of Mairs & Power Inc. , Mario Gabelli of GAMCO Investors, Chuck Royce of Royce& Associates.
Senior VP and CFO James R Giertz bought shares of FUL stock.
For details of insider trades and ownership of FUL, click here
Spectrum Pharma (SPPI, Financial): Acting CFO Brett L Scott Bought 4,000 Shares
Acting CFO of Spectrum Pharma (SPPI) Brett L Scott bought 4,000 shares on 01/20/2011 at an average price of $6.05. Spectrum Pharmaceuticals, Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum Pharma has a market cap of $316.5 million; its shares were traded at around $6.33 with and P/S ratio of 8.3.
Spectrum Pharmaceuticals, Inc. reported financial results for the three and nine-months ended September 30. The Company recorded a net loss of $4.6 million, or ($0.09) per basic and diluted share, compared to net income of $474 thousand, or $0.01 per basic and ($0.07) per diluted share, in the third quarter of 2009.
Acting CFO Brett L Scott and CSO AND HEAD OF R&D OPERATIONS George F Tidmarsh bought shares of SPPI stock.
For details of insider trades and ownership of SPPI, click here
NAIC Growth Fund Inc (GRF, Financial): CFO, COO and secretary David C Sims Bought 1,667 Shares
CFO, COO and secretary of NAIC Growth Fund Inc (GRF) David C Sims bought 1,667 shares on 01/19/2011 at an average price of $6.55. Naic Growth Fund Inc has a market cap of $26.6 million; its shares were traded at around $6.6501 . The dividend yield of Naic Growth Fund Inc stocks is 1.5%.
President and CEO Luke E Sims sold shares of GRF stock.
Biosante Pharma (BPAX, Financial): Sr. VP of Finance, CFO & Sec'y Philip B Donenberg Bought 2,000 Shares
Sr. VP of Finance, CFO & Sec'y of Biosante Pharma (BPAX) Philip B Donenberg bought 2,000 shares during the past week at an average price of $1.88. Biosante Pharmaceutical is an emerging pharmaceutical company developing a pipeline of hormone therapy products to treat both men and women. Biosante Pharma has a market cap of $132.4 million; its shares were traded at around $1.87 with and P/S ratio of 105.2.
BioSante Pharmaceuticals, Inc. announced its third quarter 2010 financial results. BioSante incurred a net loss of approximately $11.6 million or ($0.16) per share for the quarter ended September 30, 2010, compared to a net loss of $6.4 million or ($0.21) per share for the same period in 2009.
Vice Chairman, President & CEO Stephen M Simes, Director Louis W Sullivan, and Director Ross J Mangano bought shares of BPAX stock.
For details of insider trades and ownership of BPAX, click here
